Therapeutic Education in Parkinson's Disease: What Impact on Drug Representations of Patients?
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Evolution of Drug representation in Patients : Verbal association
研究概览
简要总结
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management. This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group.
详细描述
Dopaminergic drug can have adverse effects leading to potential serious consequences. Therapeutic patient education must promote the understanding of drugs to improve its management.
The therapeutic educational program ETPARK includes individual's consults or workshop. The team frequently offer to patients to participate in workshop on Parkinson disease's drug.
This study tries to evaluate the effect of therapeutic education workshop on Parkinson disease's drug (drug workshop) on the evolution of drug's representations in patients with Parkinson's disease compared to a control group (speaking group) at 1 and 3 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with Parkinson's disease according to the United Kingdom Parkinson Disease Society Brain Bank (UKPDSBB) criteria,
- •Patients who are already in therapeutic education program ETPARK,
- •Patients who need and want to participate in therapeutic education workshop on Parkinson disease drug,
- •Patients with health insurance,
- •Patients who have signed a written informed consent form.
排除标准
- •Patients suffering from another parkinsonian syndrome (multiple system atrophy, progressive supranuclear palsy etc.),
- •Patients who has already done workshop on Parkinson disease drug (program ETPARK)
- •Patients already included in clinical trial during the study,
- •Patients who have severe psychiatric disorders or dopaminergic psychosis,
- •Patients with cognitive impairment,
- •Patients unable to complete the various scales used in the study,
- •Patients under juridical protection,
- •Women pregnant or breastfeeding.
研究组 & 干预措施
Therapeutic education workshop
Two group receive therapeutic education workshop already existing in Toulouse University Hospital
干预措施: Therapeutic education workshop (Other)
Speaking Therapy
One group receive speaking therapy already existing in Toulouse University Hospital
干预措施: Speaking Therapy (Other)
结局指标
主要结局
Evolution of Drug representation in Patients : Verbal association
时间窗: Three months
Evolution of Drug representation through verbal association tasks compared to the control group. Evolution will be compared between the Baseline and the end of the study
Evolution of Drug representation in Patients : BMQ
时间窗: Three months
Evolution of Drug representation through the Believe about Medicines Questionnaire (BMQ) compared to the control group. Evolution will be compared between the Baseline and the end of the study BMQ with eighteen items coded from 1 " "strongly agree" to 5 "strongly disagree".
次要结局
- Drug representation in caregivers : Verbal association(Day 1)
- Drug representation in caregivers : BMQ(Day 1)
- Evolution in life quality : PDQ-(39)(three months)
- Knowledge about the disease(three months)
- Evolution in life quality : VAS(three months)